A Phase I/Ib Study of the CDK Inhibitor Dinaciclib in CLL

February 7, 2014
John C. Byrd, MD

John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Clinical Pearls

John C. Byrd, MD, director of the division of hematology and a CLL specialist at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

  • Dinaciclib is a second-generation selective inhibitor of CDKs 1, 2, 5, and 9
  • This agent was evaluated in a phase I/Ib expansion study in patients with relapsed or refractory CLL
  • Unlike early CDK inhibitors, dinaciclib induced a high response rate (65-70%) and durable remissions